1. Home
  2. INTR vs IDYA Comparison

INTR vs IDYA Comparison

Compare INTR & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

INTR

Inter & Co. Inc.

HOLD

Current Price

$5.44

Market Cap

2.7B

Sector

N/A

ML Signal

HOLD

Logo IDEAYA Biosciences Inc.

IDYA

IDEAYA Biosciences Inc.

HOLD

Current Price

$36.74

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INTR
IDYA
Founded
1994
2015
Country
Brazil
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
2.6B
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
INTR
IDYA
Price
$5.44
$36.74
Analyst Decision
Buy
Strong Buy
Analyst Count
2
16
Target Price
$10.00
$52.86
AVG Volume (30 Days)
5.4M
1.3M
Earning Date
05-11-2026
05-06-2026
Dividend Yield
1.51%
N/A
EPS Growth
N/A
61.90
EPS
N/A
N/A
Revenue
N/A
$218,710,000.00
Revenue This Year
$84.07
N/A
Revenue Next Year
$18.26
$201.05
P/E Ratio
$16.39
N/A
Revenue Growth
N/A
3024.43
52 Week Low
$5.16
$20.50
52 Week High
$10.36
$39.28

Technical Indicators

Market Signals
Indicator
INTR
IDYA
Relative Strength Index (RSI) 34.93 72.78
Support Level N/A $32.85
Resistance Level $6.10 $38.15
Average True Range (ATR) 0.22 1.95
MACD 0.01 0.82
Stochastic Oscillator 22.34 83.38

Price Performance

Historical Comparison
INTR
IDYA

About INTR Inter & Co. Inc.

Inter & Co Inc operates as a digital bank. The company's segment includes Banking & Spending; Investments; Insurance Brokerage; and Inter Shop. It generates maximum revenue from the Banking & Spending segment which comprises a wide range of banking products and services, such as checking accounts, cards, deposits, loans and advances, and other services, which are available to the clients by means of Inters mobile application.

About IDYA IDEAYA Biosciences Inc.

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

Share on Social Networks: